Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

TOKYO, Dec 20, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation... » read more

Asian and Pacific Countries Adopt Jakarta Declaration 2023-2032
Asian and Pacific Countries Adopt Jakarta Declaration 2023-2032

JAKARTA, Oct 24, 2022 – (ACN Newswire via SEAPRWire.com) – The ‘High-level Intergovernmental Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities’ (HLIGM APDPD) closed on Friday (Oct 21) with 53 Asia-Pacific and 9 associated countries adopting the landmark Jakarta Declaration, marking the start of the fourth ‘Asian and... » read more

U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab
U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab

TOKYO, Jul 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild... » read more

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

TOKYO, Sep 28, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early... » read more

Network of 1,200 migrant worker volunteers provide social support in dorms

SINGAPORE – For many of the 8,000 migrant workers living in PPT Lodge 1B dormitory, Mr Letchumanan Muralidharan, 47, has been their translator, mediator and confidant. When the dorm, also known as S11 Dormitory @ Punggol, was locked down on April 5 last year after being declared an isolation area, the construction worker from India... » read more

New treatment option for schizophrenia Reagila(R) listed on PBS
New treatment option for schizophrenia Reagila(R) listed on PBS

MELBOURNE, Sep 6, 2021 – (ACN Newswire via SEAPRWire.com) – A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for... » read more

New treatment option for schizophrenia – Reagila(R) – listed on PBS this week
New treatment option for schizophrenia – Reagila(R) – listed on PBS this week

– Adults living with schizophrenia will have access to a new treatment option with Reagila(R) (cariprazine) now reimbursed on the Pharmaceutical Benefits Scheme from 1 September, 2021.1 – There continues to be a significant, unmet need in treating schizophrenia. With a complex range of symptoms,2 treatment is not a “one size fits all”.3 This listing... » read more

Live shows from his living room help migrant workers stave off lockdown woes

SINGAPORE – For the past 16 months, since movement within migrant workers’ dormitories began to be restricted, one man has been trying to keep his fellow Bangladeshis here informed and entertained from his living room in Tampines. For an hour or two each Saturday, Mr Nazmul Khan, 40, transports migrant workers out of their dorm... » read more